• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

"The global pharmaceutical market grew to US$712 billion in 2007, growing at a compound annual growth rate (CAGR) of 10.0% between 1999 and 2007. Year-on-year growth in the global pharmaceutical market increased to 10.7% in 2007, largely as a result of strong sales growth for new innovative products and high market growth in emerging pharmaceutical markets such as China."

2008 updated version of this best-selling report!

Pharmaceutical Market Trends, 2008 - 2012: Key market forecasts & growth opportunities presents a detailed trend analysis of the global pharmaceutical market as at the end of 2006 and forecasts until 2012. The 142 page report presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

The data and analysis contained within the report are comprehensive, consistent and up-to-date in order to provide a single-point reference for understanding key pharmaceutical market trends in 2008.

KEY FINDINGS INCLUDE

 

• The global pharmaceutical market is forecast to grow to US$929 billion in 2012, an equivalent compound annual growth rate (CAGR) of 5.5% over the next five years.
  
• In 2007 the leading therapy areas by sales were CNS with 16.5% share and cardiovascular with 15.4%.
• Four of the top 10 products in 2007 are forecast to increase sales over the next five years.
• The US retail pharmaceutical market grew to US$206 billion but growth rates fell due to loss of patent protection on some blockbusters
• France, Germany and the UK together accounted for almost 50% of all European pharmaceutical sales in 2007.
• TThe top 100 blockbuster drugs generated sales of US$252.5 billion, accounting for 35.5% of the total pharmaceutical market.
  
• The leading blockbuster by increased sales revenues in 2007 was the blood agent product Plavix (clopidogrel bisulfate), marketed by Sanofi-Aventis and Bristol-Myers Squibb.
• There were a total of 61 companies generating pharmaceutical sales in excess of US$1 billion in 2007
  
  

KEY FEATURES OF THE REPORT

• Comprehensive market trends for key countries, regions , therapy areas, products and companies.
• Country profiles for leading pharma markets with market segment trends and 5 year forecasts.
• Therapy area profiles for leading therapeutic classes and key products and 2012 sales forecasts.
• Detailed profiles of 10 leading pharmaceutical products in 2008, including five year future sales forecasts.
• Detailed profiles of 10 leading pharmaceutical companies in 2008, including 2012 sales forecasts.(AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi-Aventis Wyeth)

 

USE THIS REPORT TO:

1. Quickly gain an overview into the global pharmaceutical market and its major companies and products.

2. Identify key areas of pharmaceutical market growth and key opportunities for delivering successful sales growth over the next five years.

3. Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.

REPORT COVERAGE
The report methodology provides a detailed but transparent analysis of key pharmaceutical market trends, including key markets, therapy areas, products and companies. Historical trends are formed over a three-year time horizon and future forecasts are made using a five-year future time period. Thus, the data and analysis relate to the nine-year time horizon from 2005 to 2012.

All data used in outlining historical trends is clearly sourced within the report and any data limitations or additional assumptions are explicitly detailed within the text of the report. Future market forecasts are projected based on both historical trends and future expectations over market conditions and events. The assumptions used to form the basis of key market forecasts are outlined in detail within the text of the report.

Executive Summary
Introduction
Key global markets
Key therapeutic markets
Key products
Key companies
Key trends and opportunities

Chapter 1 Introduction
Global pharmaceutical market
Report overview
Chapter 2 Key global markets
Key pharmaceutical markets
US pharmaceutical market
European pharmaceutical market

Japanese pharmaceutical market

Chapter 3 Key therapeutic markets
Key therapy areas
CNS therapy area
Cardiovascular therapy area
Alimentary/metabolism therapy area
Anti-infectives therapy area
Respiratory therapy area
Oncologics therapy area

Chapter 4 Key products
Leading products

Blockbuster trends

Chapter 5 Key companies
Major pharmaceutical companies
Top 10 pharmaceutical companies
Top 10 company financials
Top 10 company value drivers
Leading pharmaceutical companies
Chapter 6 Key trends and opportunities
Global market forecasts
Key therapy area forecasts
Key product forecasts
Key company forecasts
Appendix
Proprietary data sources

Top 117 pharmaceutical products
Top 61 pharmaceutical companies

LIST OF FIGURES

Figure 1: Global pharmaceutical market, 1999-2007
Figure 2: Report structure
Figure 3: Global pharmaceutical market share by region, 2007
Figure 4: Global pharmaceutical market by region, 2003-2007
Figure 5: US pharmaceutical market, 2003-2007
Figure 6: US pharmaceutical market share by purchasing channel, 2007
Figure 7: US pharmaceutical market by purchasing channel, 2003-2007
Figure 8: US retail pharmaceutical market, 2003-2007
Figure 11: Top 10 products by US pharmaceutical sales, 2007
Figure 12: Top 10 companies by US pharmaceutical sales, 2007
Figure 13: Top 10 companies by share of US pharmaceutical sales, 2007
Figure 14: European pharmaceutical market, 2003-2007
Figure 15: European pharmaceutical market share by country, 2007
Figure 16: European top 5 retail pharmaceutical market, 2003-2007
Figure 17: European top 5 retail pharmaceutical market share by country, 2007
Figure 18: European top 5 retail pharmaceutical market by country, 2003-2007
Figure 21: Japanese pharmaceutical market, 2003-2007
Figure 24: Global pharmaceutical market by therapy area, 2007
Figure 25: Top 10 product classes by global pharmaceutical sales, 2007
Figure 31: CNS pharmaceutical market, 2005-2007
Figure 28: Cardiovascular pharmaceutical market, 2005-2007
Figure 34: Alimentary/metabolism pharmaceutical market, 2005-2007
Figure 40: Anti-infectives pharmaceutical market, 2005-2007
Figure 37: Respiratory pharmaceutical market, 2005-2007
Figure 46: Oncologics pharmaceutical market, 2005-2007
Figure 49: Blockbuster drug sales share by drug type, 2007
Figure 50: Blockbuster drug sales share by lifecycle stage, 2007
Figure 51: Blockbuster drug sales share by therapy area, 2007
Figure 52: Blockbuster drug sales share by company, 2007
Figure 53: Major companies pharmaceutical sales, 2003-2007
Figure 54: Major companies revenue share allocation, 2007
Figure 55: Major companies revenue allocation, 2003-2007
Figure 56: Major companies pharmaceutical sales by location, 2007
Figure 57: Top 10 pharma companies pharmaceutical sales, 2003-2007
Figure 58: Top 10 pharma companies by global pharmaceutical sales, 2007
Figure 59: Top 10 biotechnology companies by global revenues, 2007
Figure 60: Top 10 pharma companies revenue share allocation, 2007
Figure 61: Top 10 pharma companies revenue allocation, 2003-2007
Figure 62: Key value drivers for top 10 pharma companies (income), 2007
Figure 63: Key value drivers for top 10 pharma companies (sales), 2007
Figure 64: Key value drivers for top 10 pharma companies (sales/R&D), 2007
Figure 65: Pfizer therapy area sales, 2003-2007
Figure 66: GlaxoSmithKline therapy area sales, 2003-2007
Figure 67: Sanofi-Aventis blockbuster therapy area sales, 2003-2007
Figure 68: Roche therapy area sales, 2003-2007
Figure 69: AstraZeneca therapy area sales, 2003-2007
Figure 70: Johnson and Johnson blockbuster therapy area sales, 2003-2007
Figure 71: Novartis therapy area sales, 2003-2007
Figure 72: Merck & Co blockbuster therapy area sales, 2003-2007
Figure 73: Wyeth blockbuster therapy area sales, 2003-2007
Figure 74: Eli Lilly therapy area sales, 2003-2007
Figure 75: Global pharmaceutical market forecast, 2003-2012
Figure 76: Global pharmaceutical market forecast by regions, 2003-2012
Figure 77: Top 10 pharmaceutical drugs by forecast sales, 2012
Figure 78: Lipitor (atorvastatin) forecast sales, 2003-2012
Figure 80: Plavix (clopidogrel) forecast sales, 2003-2012
Figure 79: Advair/Seretide (fluticasone/salmeterol) forecast sales, 2003-2012
Figure 83: Enbrel (etanercept) forecast sales, 2003-2012
Figure 82: Nexium (esomeprazole) forecast sales, 2003-2012
Figure 84: Remicade (infliximab) forecast sales, 2003-2012
Figure 87: Diovan/Co-Diovan (valsartan/hydrochlorothiazide) forecast sales, 2003-2012
Figure 85: Zyprexa (olanzapine) forecast sales, 2003-2012
Figure 81: Rituxan (rituximab) forecast sales, 2003-2012
Figure 86: Risperdal (risperidone) forecast sales, 2003-2012

LIST OF TABLES

Table 1: Global pharmaceutical market trends by region, 2005-2007
Table 2: US pharmaceutical market trends by purchasing channel, 2005-2007
Table 4: Top 10 products trends by US pharmaceutical sales, 2005-2007
Table 5: European top 5 retail pharmaceutical market trends by country, 2005-2007
Table 1: Global pharmaceutical market trends by therapy area, 2005-2007
Table 8: Top 10 product classes trends by global pharmaceutical sales, 2005-2007
Table 13: CNS blockbuster drug sales, 2005-2007
Table 11: Cardiovascular blockbuster drug sales, 2005-2007
Table 15: Alimentary/metabolism blockbuster drug sales, 2005-2007
Table 19: Anti-infectives blockbuster drug sales, 2005-2007
Table 17: Respiratory blockbuster drug sales, 2005-2007
Table 23: Cytostatics blockbuster drug sales, 2005-2007
Table 24: Top 20 products by global pharmaceutical sales, 2005-2007
Table 25: Lipitor (atorvastatin) profile, 2007
Table 26: Plavix (clopidogrel) profile, 2007
Table 27: Advair/Seretide (fluticasone/salmeterol) profile, 2007
Table 28: Enbrel (etanercept) profile, 2007
Table 29: Nexium (esomeprazole) profile, 2007
Table 30: Remicade (infliximab) profile, 2007
Table 31: Diovan/Co-Diovan/Provas/Miten (valsartan/hydrochlorothiazide) profile, 2007
Table 32: Zyprexa (olanzapine) profile, 2007
Table 33: Rituxan (rituximab) profile, 2007
Table 34: Risperdal (risperidone) profile, 2007
Table 35: Top 10 blockbuster products by global pharmaceutical sales growth, 2005-2007
Table 36: Top 10 blockbuster products by declining global pharmaceutical sales, 2005-2007
Table 37: New blockbuster products, 2005-2007
Table 38: Major companies revenue allocation trends, 2005-2007
Table 39: Top 10 pharma companies by global pharmaceutical sales, 2005-2007
Table 40: Top 10 biotechnology companies by global revenues, 2005-2007
Table 41: Top 10 pharma companies revenue allocation trends, 2005-2007
Table 42: Pfizer profile, 2007
Table 43: Pfizer blockbuster sales, 2005-2007
Table 44: GlaxoSmithKline profile, 2007
Table 45: GlaxoSmithKline blockbuster sales, 2005-2007
Table 46: Sanofi-Aventis profile, 2007
Table 47: Sanofi-Aventis blockbuster sales, 2005-2007
Table 48: Roche profile, 2007
Table 49: Roche blockbuster sales, 2005-2007
Table 50: AstraZeneca profile, 2007
Table 51: AstraZeneca blockbuster sales, 2005-2007
Table 52: Johnson and Johnson profile, 2007
Table 53: Johnson and Johnson blockbuster sales, 2005-2007
Table 54: Novartis profile, 2007
Table 55: Novartis blockbuster sales, 2005-2007
Table 56: Merck & Co profile, 2007
Table 57: Merck & Co blockbuster sales, 2005-2007
Table 58: Wyeth profile, 2007
Table 59: Wyeth blockbuster sales, 2005-2007
Table 60: Eli Lilly profile, 2007
Table 61: Eli Lilly blockbuster sales, 2005-2007
Table 62: Global pharmaceutical market forecast by regions, 2003-2012
Table 63: Global pharmaceutical market forecast by therapy area, 2007-2012
Table 64: Top 10 pharmaceutical drugs forecast, 2003-2012
Table 65: Top 10 pharmaceutical companies forecast, 2007-2012
Table 66: Top 117 products by global pharmaceutical sales, 2005-2007
Table 67: Top 61 companies by global pharmaceutical sales, 2005-2007

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries.

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the portfolio management and licensing functions.